Table 2.
Independent risk factors for therapeutic effectiveness on progression-free survival determined by Cox regression analysis.
| All patients | Patients with radiotherapy history | Recurrences only within the pelvic cavity | Recurrences only within the pelvic cavity and with radiotherapy history | Recurrences only beyond the pelvic cavity | Recurrences both within and beyond the pelvic cavity | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| Histological pathology | 0.271 | 0.901 | 0.839 | 0.561 | 0.487 | 0.716 | ||||||
| SCC | Reference | – | Reference | – | Reference | – | Reference | – | Reference | – | Reference | – |
| Endocervical ADC | 1.3 (0.8-2.0) | 0.202 | 1.1 (0.6-1.8) | 0.830 | 1.2 (0.6-2.3) | 0.594 | 0.5 (0.2-1.7) | 0.282 | 1.7 (0.3-8.9) | 0.503 | 1.0 (0.5-2.1) | 0.901 |
| Adenosquamous carcinoma | 1.7 (0.7-3.8) | 0.221 | 1.3 (0.4-4.4) | 0.665 | 1.2 (0.4-4.5) | 0.725 | 0.0 (0.0-N/A) | 0.982 | 2.7 (0.4-17.2) | 0.290 | 1.9 (0.4-8.4) | 0.414 |
| Primary stages | 0.539 | 0.258 | 0.115 | 0.707 | 0.097 | 0.805 | ||||||
| Early stages | Reference | – | Reference | – | Reference | – | Reference | – | Reference | – | Reference | – |
| Locally advanced stages | 1.2 (0.8-1.8) | 0.271 | 0.6 (0.4-1.1) | 0.102 | 1.8 (1.0-3.1) | 0.039 | 1.5 (0.6-3.8) | 0.432 | 0.5 (0.2-1.7) | 0.285 | 0.9 (0.4-1.7) | 0.723 |
| Advanced stages | 1.2 (0.6-2.5) | 0.685 | 0.6 (0.3-1.4) | 0.242 | 1.5 (0.3-7.5) | 0.643 | 1.2 (0.2-7.7) | 0.855 | 0.1 (0.02-0.9) | 0.036 | 1.2 (0.4-3.9) | 0.745 |
| Primary treatment regimens | 0.435 | 0.510 | 0.891 | 0.154 | 0.187 | 0.098 | ||||||
| Only radiotherapy or CCRT | Reference | – | Reference | – | Reference | – | Reference | – | Reference | – | Reference | – |
| Radiotherapy or CCRT plus chemotherapy | 1.2 (0.6-2.6) | 0.549 | 1.5 (0.7-3.2) | 0.317 | 1.0 (0.1-8.7) | 0.978 | 2.1 (0.2-21.7) | 0.534 | 1.3 (0.3-5.8) | 0.703 | 3.8 (1.0-14.1) | 0.045 |
| Surgery with/without adjuvant therapy | 0.8 (0.5-1.2) | 0.313 | 0.9 (0.6-1.5) | 0.720 | 1.2 (0.6-2.2) | 0.635 | 2.1 (1.0-4.6) | 0.054 | 0.4 (0.1-1.1) | 0.081 | 1.0 (0.4-2.0) | 0.897 |
| Treatment regimens for recurrence* | 0.029 | 0.255 | 0.005 | 0.270 | 0.089 | 0.415 | ||||||
| Single radiotherapy | Reference | – | Reference | – | Reference | – | Reference | – | Reference | – | Reference | – |
| Combination therapy | 1.4 (1.0-2.0) | 0.088 | 1.0 (0.6-1.6) | 0.974 | 1.6 (1.0-2.8) | 0.072 | 1.6 (0.7-3.8) | 0.264 | 0.2 (0.1-0.8) | 0.028 | 1.2 (0.7-2.4) | 0.460 |
| Single Surgical therapy | 1.8 (1.0-3.3) | 0.048 | 1.6 (0.7-3.3) | 0.239 | 3.0 (1.3-6.7) | 0.009 | 2.5 (0.9-6.7) | 0.069 | 0.6 (0.05-7.2) | 0.696 | 0.8 (0.3-2.6) | 0.770 |
| Single chemotherapy | 2.0 (1.2-3.2) | 0.006 | 1.5 (0.9-2.8) | 0.142 | 3.6 (1.6-7.9) | 0.002 | 2.2 (0.7-6.6) | 0.167 | 0.5 (0.1-1.9) | 0.308 | 0.6 (0.21.6-) | 0.339 |
*Ablative therapy was combined with surgical therapy.
95% CI, 95% confidential interval; ADC, adenocarcinoma; CCRT, concurrent chemoradiotherapy; HR, hazard ratio; NA, not available. SCC, squamous cell carcinoma.
The bold figures are p values <0.05.